COMPARISON
Ciclosporin vs Leuprolide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Ciclosporin is authorised or registered in 9 and Leuprolide in 8 of the 10 registers read. Ciclosporin: highest phase Phase 4 (after approval). Leuprolide: highest phase Phase 3 (2 phase 3 trials, 0 with posted results). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Ciclosporin | Leuprolide | |
|---|---|---|
| Registered trials differs | 1328 clinicaltrials.gov · 2026-10-03 | 520 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA label, application not recorded: VEVYE openfda · 2026-08-31T07:37:14Z | FDA-approved: Vabrinty openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2015-03-19 ema · 2026-10-03 | Not checked no record of "authorisedOn" for leuprolide |
| ATC code differs | S01XA18 ema · 2026-10-03 | Not checked no record of "atcCode" for leuprolide |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Ciclosporin | placebo | Leuprolide | placebo |
|---|---|---|---|---|
| Punctate Keratitis | 5.8% | 4.5% | - | - |
| Hot flush | - | - | 68.8% | 57.3% |
| Fatigue | - | - | 42.8% | 32.8% |
| Arthralgia | - | - | 27.5% | 20.9% |
| Fall | - | - | 20.4% | 14.1% |
| Back pain | - | - | 17.0% | 15.3% |
| Hypertension | - | - | 16.4% | 15.1% |
| Diarrhoea | - | - | 13.9% | 8.5% |
| Asthenia | - | - | 11.0% | 5.9% |
| Pain in extremity | - | - | 11.0% | 10.2% |
| Dizziness | - | - | 11.0% | 10.5% |
Trial register Ciclosporin: 7 placebo-controlled trials; Leuprolide: 2. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Ciclosporin side effects · Leuprolide side effects
LEGAL STATUS
Approval in each country read
| Country | Ciclosporin | Leuprolide | Register |
|---|---|---|---|
| United States | FDA label, application not recorded | FDA-approved | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.